You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 27, 2024

Details for Patent: 10,966,984


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 10,966,984 protect, and when does it expire?

Patent 10,966,984 protects COSELA and is included in one NDA.

This patent has fifty-three patent family members in seventeen countries.

Summary for Patent: 10,966,984
Title:Transient protection of normal cells during chemotherapy
Abstract: This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
Inventor(s): Strum; Jay Copeland (Hillsborough, NC), Bisi; John Emerson (Chapel Hill, NC), Roberts; Patrick Joseph (Durham, NC), Tavares; Francis Xavier (Durham, NC)
Assignee: G1 Therapeutics, Inc. (Research Triangle Park, NC)
Application Number:16/112,360
Patent Claim Types:
see list of patent claims
Use;
Patent landscape, scope, and claims:

United States Patent 10,966,984: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 10,966,984, titled "Transient protection of normal cells during chemotherapy," is a significant invention in the field of oncology and pharmacology. This patent, granted to protect innovative compounds, compositions, and methods, aims to safeguard healthy cells from the detrimental effects of chemotherapy. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Background and Motivation

Chemotherapy, a cornerstone in cancer treatment, often causes collateral damage to healthy cells, particularly hematopoietic stem cells. This patent addresses the need for transient protection of these cells, enhancing the efficacy and safety of chemotherapy regimens[4].

Scope of the Patent

The patent covers a range of innovations including:

Improved Compounds

The invention involves the development of new compounds and compositions that can transiently protect normal cells, especially hematopoietic stem cells, during chemotherapy. These compounds are designed to mitigate the cytotoxic effects of chemotherapeutic agents without compromising their anti-cancer efficacy[4].

Methods of Protection

The patent describes methods for administering these protective compounds before, during, or after chemotherapy. This temporal approach ensures that healthy cells are shielded from damage while cancer cells remain vulnerable to the therapeutic agents[4].

Specific Applications

The patent includes claims for the use of these compounds in protecting against various types of cancer, including small cell lung carcinoma, triple-negative breast carcinoma, and other neoplasms. It also covers the protection of bone marrow cells, which are often affected by chemotherapy[4].

Claims of the Patent

The claims of the patent are detailed and specific, outlining the following key aspects:

Compound Claims

  • The patent claims cover specific chemical compounds, including CDK 4/6 inhibitors, and their salts. These compounds are crucial for transiently protecting healthy cells from chemotherapeutic agents[4].

Method Claims

  • The method claims describe the process of administering these protective compounds in conjunction with chemotherapy. This includes the timing and dosage of the protective agents relative to the chemotherapeutic agents[4].

Use Claims

  • The patent claims also specify the use of these compounds in treating various cancers and protecting specific cell types, such as hematopoietic stem cells[4].

Patent Landscape

Prior Art

The patent references prior art related to chemotherapeutic agents and cell protection methods. It highlights the limitations of existing methods and the need for more effective and targeted approaches to protect healthy cells during chemotherapy[4].

International Patent Offices

To understand the global patent landscape, it is essential to search international patent databases. Resources like the European Patent Office (EPO), Japan Patent Office (JPO), and the World Intellectual Property Organization (WIPO) provide access to international patent applications and granted patents. This helps in identifying similar inventions and ensuring that the patent in question does not infringe on existing global patents[1].

Related Patents and Applications

The Common Citation Document (CCD) application is useful for consolidating prior art cited by multiple patent offices for the same invention. This tool helps in visualizing the global patent landscape and identifying potential overlaps or conflicts with other patents[1].

Search and Analysis Tools

USPTO Resources

The United States Patent and Trademark Office (USPTO) offers several tools for searching and analyzing patents. The Patent Public Search tool, for instance, provides enhanced access to prior art and is a valuable resource for conducting comprehensive patent searches[1].

Global Dossier

The Global Dossier service allows users to access the file histories of related applications from participating IP Offices. This service is crucial for understanding the international patent family and any office actions related to the patent[1].

Economic and Research Implications

Patent Claims Research Dataset

The USPTO's Patent Claims Research Dataset provides detailed information on claims from US patents and patent applications. This dataset can be used to analyze trends in patent scope and claims, offering insights into the broader patent landscape and the economic implications of such inventions[3].

Industry Impact

The invention covered by this patent has significant implications for the pharmaceutical industry. By protecting healthy cells during chemotherapy, it can improve patient outcomes, reduce side effects, and potentially increase the market for chemotherapeutic agents. This could lead to new business opportunities and collaborations between pharmaceutical companies and research institutions.

Key Takeaways

  • Innovation in Cell Protection: The patent introduces novel compounds and methods for transiently protecting healthy cells during chemotherapy.
  • Specific Claims: The patent includes detailed claims on specific compounds, methods of administration, and applications in various cancer treatments.
  • Global Patent Landscape: Understanding the international patent landscape is crucial to avoid infringement and identify potential collaborations or conflicts.
  • Economic Implications: The invention has significant economic implications for the pharmaceutical industry, potentially leading to new market opportunities and improved patient outcomes.

FAQs

What is the primary focus of United States Patent 10,966,984?

The primary focus of this patent is the development of compounds, compositions, and methods for transiently protecting normal cells, especially hematopoietic stem cells, during chemotherapy.

Which types of cancer are covered by this patent?

The patent includes claims for protecting against various types of cancer, including small cell lung carcinoma, triple-negative breast carcinoma, and other neoplasms.

What tools can be used to analyze the patent landscape for this invention?

Tools such as the USPTO's Patent Public Search, Global Dossier, and the Common Citation Document (CCD) application are useful for analyzing the patent landscape.

How does this patent impact the pharmaceutical industry?

This patent can improve patient outcomes by reducing the side effects of chemotherapy, potentially increasing the market for chemotherapeutic agents and leading to new business opportunities.

Where can one find detailed information on claims from US patents and patent applications?

The USPTO's Patent Claims Research Dataset provides detailed information on claims from US patents and patent applications.

What is the significance of the Global Dossier service in patent searching?

The Global Dossier service allows users to access the file histories of related applications from participating IP Offices, providing a comprehensive view of the international patent family.

Sources

  1. USPTO - Search for patents: "How to Conduct a Preliminary U.S. Patent Search: A Step by Step Strategy."
  2. DrugPatentWatch: "Pharmaceutical drugs covered by patent 10,966,984."
  3. USPTO - Patent Claims Research Dataset: "Patent Claims Research Dataset."
  4. Google Patents: "US10966984B2 - Transient protection of normal cells during chemotherapy."
  5. PubChem: "Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation."

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 10,966,984

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pharmacosmos COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes 10,966,984 ⤷  Subscribe A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER ⤷  Subscribe
Pharmacosmos COSELA trilaciclib dihydrochloride POWDER;INTRAVENOUS 214200-001 Feb 12, 2021 RX Yes Yes 10,966,984 ⤷  Subscribe A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE- STAGE SMALL CELL LUNG CANCER ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,966,984

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada 2906156 ⤷  Subscribe
Canada 2906157 ⤷  Subscribe
Canada 2906166 ⤷  Subscribe
Canada 3152117 ⤷  Subscribe
China 105407723 ⤷  Subscribe
China 105407889 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.